Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Atreca stock | 15.26

Own Atreca stock in just a few minutes.

Posted

Fact checked

Atreca, Inc is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Atreca employs 118 staff and has a market cap (total outstanding shares value) of USD$539 million.

How to buy shares in Atreca

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Atreca. Find the stock by name or ticker symbol: BCEL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Atreca reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$15.26, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Atreca, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Atreca. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Atreca's share price?

Since the stock market crash in March caused by coronavirus, Atreca's share price has had significant negative movement.

Its last market close was USD$15.26, which is 31.91% down on its pre-crash value of USD$22.41 and 40.25% up on the lowest point reached during the March crash when the shares fell as low as USD$10.8807.

If you had bought USD$1,000 worth of Atreca shares at the start of February 2020, those shares would have been worth USD$749.33 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$805.27.

Atreca share price

Use our graph to track the performance of BCEL stocks over time.

Atreca shares at a glance

Information last updated 2020-10-19.
Latest market close USD$15.26
52-week range USD$9.51 - USD$29.35
50-day moving average USD$14.0819
200-day moving average USD$16.1761
Wall St. target price USD$28.86
PE ratio 4.5749
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-18.879

Buy Atreca shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Atreca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atreca price performance over time

Historical closes compared with the close of $15.26 from 2020-11-16

1 week (2020-11-19) 4.95%
1 month (2020-10-26) 8.07%
3 months (2020-08-26) 11.14%
6 months (2020-05-26) -19.51%
1 year (2019-11-26) 57.64%
2 years (2018-11-23) N/A
3 years (2017-11-23) N/A
5 years (2015-11-23) N/A

Is Atreca under- or over-valued?

Valuing Atreca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atreca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Atreca's P/E ratio

Atreca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Atreca shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Atreca financials

Gross profit TTM USD$0
Return on assets TTM -25.79%
Return on equity TTM -40.96%
Profit margin 0%
Book value $7.332
Market capitalisation USD$539 million

TTM: trailing 12 months

Shorting Atreca shares

There are currently 3.5 million Atreca shares held short by investors – that's known as Atreca's "short interest". This figure is 39% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting Atreca shares can be evaluated.

Atreca's "short interest ratio" (SIR)

Atreca's "short interest ratio" (SIR) is the quantity of Atreca shares currently shorted divided by the average quantity of Atreca shares traded daily (recently around 286341.69407895). Atreca's SIR currently stands at 12.16. In other words for every 100,000 Atreca shares traded daily on the market, roughly 12160 shares are currently held short.

However Atreca's short interest can also be evaluated against the total number of Atreca shares, or, against the total number of tradable Atreca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atreca's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Atreca shares in existence, roughly 100 shares are currently held short) or 0.1632% of the tradable shares (for every 100,000 tradable Atreca shares, roughly 163 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Atreca.

Find out more about how you can short Atreca stock.

Atreca share dividends

We're not expecting Atreca to pay a dividend over the next 12 months.

Atreca overview

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a strategic research collaboration with Merck Sharp & Dohme Corp. to identify the antigenic targets of select antibodies discovered with potential utility in oncology. Atreca, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site